SENSIMED Triggerfish

Status Completed

Clinical Trial Summary

The purpose of the investigation is to investigate the relationship between the study device output and tonometric assessments.

Clinical Trial Description

60 subjects will be enrolled in total. Enrolled patients will be randomized into one of 8 device groups of 6 subjects each or into the control group containing 12 subjects. Patients in the device arm will receive one session of 3-to 24-hour continuous IOP monitoring with SENSIMED Triggerfish®. SENSIMED Triggerfish® monitoring will begin at 18h ± 2 hours for all patients. SENSIMED Triggerfish® will be installed randomly on right or left eyes. During SENSIMED Triggerfish® monitoring on one eye, GAT and/or Perkins IOP measurements will be taken in the fellow eye every 3 hours. Outside this time they will receive GAT and/or IOP measurements every 3 hours in both eyes until the end of the 24-hours period. Patients in the control group will receive GAT and/or ICare PRO IOP measurements every 3 hours for 24 hours in both eyes. ;

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

Glaucoma

Clinical Trial Details

NCT number	NCT01319604
Study type	Interventional
Source	Sensimed AG
Contact
Status	Completed
Phase	N/A
Start date	March 2011
Completion date	May 2012

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06000865` - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE	N/A
Recruiting	`NCT06278597` - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device	N/A
Active, not recruiting	`NCT04271709` - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)	N/A
Recruiting	`NCT03274024` - The Asia Primary Tube Versus Trab (TVT) Study	N/A
Completed	`NCT04552964` - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma	N/A
Recruiting	`NCT01957267` - Functional and Structural Imaging for Glaucoma
Active, not recruiting	`NCT04624698` - iStent Inject New Enrollment Post-Approval Study	N/A
Completed	`NCT04020705` - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma	N/A
Completed	`NCT03150160` - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma	Phase 4
Not yet recruiting	`NCT05581498` - Glaucoma Exercise as Medicine Study (GEMS).	N/A
Recruiting	`NCT02921568` - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes	N/A
Active, not recruiting	`NCT02901730` - Clinical Study of LPI With Different Laser Wavelengths	N/A
Completed	`NCT02955849` - A Trial of China Laser and Surgery Study Glaucoma in Rural China	Early Phase 1
Recruiting	`NCT02471105` - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml	Phase 4
Recruiting	`NCT02554214` - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device	N/A
Active, not recruiting	`NCT02390284` - Stop Retinal Ganglion Cell Dysfunction Study	Phase 3
Completed	`NCT02520674` - Glaucoma Screening With Smartphone Ophthalmology	N/A
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Completed	`NCT02653963` - Triamcinolone for Ahmed Glaucoma Valve	N/A
Completed	`NCT02246764` - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 3